Press Releases

January 11, 2010

Stratatech to collaborate with Fortune 200 company on product development

MADISON, Wis., January 11, 2010 – Stratatech Corp. today announced that it has entered into a collaborative agreement with a Fortune 200 consumer products company to develop an advanced skin care product. The aim of the collaboration is to create a product that prevents skin wounds by enhancing the resiliency of compromised or susceptible skin. The product will be based on extracts from Stratatech’s bioengineered, living human skin tissue that expresses biologically active factors to promote healthy skin.

All of Stratatech’s skin tissue products are based on a proprietary source of clinically-tested keratinocyte cells that produce a number of factors thought to augment native skin function and accelerate wound healing. Extracts from these proprietary cells that enhance skin health will be incorporated into a topical formulation to create a product that can be used to protect aged or compromised skin.

About Stratatech Corp.

Stratatech Corp. is a Madison, Wis.-based regenerative medicine company focused on the development and commercialization of cell-based, tissue-engineered skin substitute products for therapeutic and research applications. The company’s flagship product, StrataGraft® tissue, is proceeding through clinical trials designed to support FDA approval of StrataGraft® tissue for the treatment of skin loss. The company’s valuable product pipeline is based on its patented NIKS® human keratinocyte cells and is comprised of the next generation of genetically-modified skin substitute products that have numerous advantages over skin substitutes generated from human skin sourced by conventional means. For more information about Stratatech, its technology, and product pipeline, please visit the company’s website at www.stratatechcorp.com.